| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2014 | WO2014007438A1 Aptamer for periostin and anti-cancer composition including same |
| 01/09/2014 | WO2014007412A1 Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient |
| 01/09/2014 | WO2014007402A1 Differentiation marker for and differentiation control for ocular cells |
| 01/09/2014 | WO2014007398A1 Cationic lipid |
| 01/09/2014 | WO2014007395A1 Pyrazole or thiazole derivative, salt thereof, and pest control agent |
| 01/09/2014 | WO2014007362A1 Method for separating cyclic macrolide compound |
| 01/09/2014 | WO2014007305A1 Oligonucleotide, and therapeutic agent for dyslipidemia which contains oligonucleotide as active ingredient |
| 01/09/2014 | WO2014007303A1 Therapeutic method and remedy for htlv-1-associated myelopathy patients |
| 01/09/2014 | WO2014007239A1 Composition containing amphotericin b |
| 01/09/2014 | WO2014007228A1 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| 01/09/2014 | WO2014007217A1 Antitumor effect potentiator composed of imidazooxazine compound |
| 01/09/2014 | WO2014007065A1 Solid pharmaceutical tablet, and method for producing same |
| 01/09/2014 | WO2014006867A1 Composition containing biologically active substance |
| 01/09/2014 | WO2014006625A1 Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors |
| 01/09/2014 | WO2014006585A1 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| 01/09/2014 | WO2014006576A1 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof |
| 01/09/2014 | WO2014006572A1 Selective pi3k delta inhibitors |
| 01/09/2014 | WO2014006554A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |
| 01/09/2014 | WO2014006518A1 Compounds as inhibitor of dna double-strand break repair, methods and applications thereof |
| 01/09/2014 | WO2014006414A1 Polymorphs of|n-[(r)-1 -[(s)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoy l]-2-(4-e|thoxy-phenyl)-ethyl]-benzamide hydrochloride |
| 01/09/2014 | WO2014006402A1 Orexin receptor antagonists |
| 01/09/2014 | WO2014006349A1 Lipiodol-based anti-tumour emulsion for treating cancer |
| 01/09/2014 | WO2014006307A1 Novel pyrrolidine derivatives |
| 01/09/2014 | WO2014006250A1 Use of sulphated glycolipids as promoters of neuritic growth and myelination and inhibitors of the proliferation of astroglia and microglia |
| 01/09/2014 | WO2014006130A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS |
| 01/09/2014 | WO2014006120A1 New positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/09/2014 | WO2014006117A1 New positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/09/2014 | WO2014006115A1 Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| 01/09/2014 | WO2014006110A1 Use of an inhibitor of irs-1 for treating skin disorders |
| 01/09/2014 | WO2014006097A1 Biocidal compositions |
| 01/09/2014 | WO2014006093A1 Compounds for use in polycystic kidney disease |
| 01/09/2014 | WO2014006091A1 Ticagrelor adducts with divalent metal salts |
| 01/09/2014 | WO2014006071A1 Indene derivatives, their preparation and use as medicaments |
| 01/09/2014 | WO2014006066A1 Triazole compounds as antivirals |
| 01/09/2014 | WO2014006045A1 Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy |
| 01/09/2014 | WO2014006020A1 Gpbp-1 inhibition and its therapeutic use |
| 01/09/2014 | WO2014006004A1 Abuse deterrent pharmaceutical compositions for controlled release |
| 01/09/2014 | WO2014005968A1 Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
| 01/09/2014 | WO2014005934A1 Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
| 01/09/2014 | WO2014005721A1 Use of (r)-phenylpiracetam for the treatment of parkinson's disease |
| 01/09/2014 | WO2014005720A1 Use of (r)-phenylpiracetam for the treatment of disease-associated fatigue |
| 01/09/2014 | WO2014005606A1 Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof |
| 01/09/2014 | WO2014005597A1 Rose hip composition, process for the manufacture of the rose hip composition and said composition for use in a method for the maintenance of flexible joints and decreased inflammation |
| 01/09/2014 | WO2014005596A1 Modified payload molecules and their interactions and uses |
| 01/09/2014 | WO2014005543A1 S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
| 01/09/2014 | WO2014005421A1 Benzodioxole derivative and preparation method and use thereof |
| 01/09/2014 | WO2014005408A1 Antibiotic tetrathiazomycin a and preparation method thereof and use in preparation of antitumour drug |
| 01/09/2014 | WO2014005363A1 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol soft capsule and method for preparing same |
| 01/09/2014 | WO2014005274A1 Multi-substituted 8-nitrogen heterocyclic ring [3.2.1] octane compound |
| 01/09/2014 | WO2014005224A1 Quercetin-3-glucoside and uses thereof |
| 01/09/2014 | WO2014005186A1 Methods for inhibiting neuron apoptosis and necrosis |
| 01/09/2014 | WO2014005182A1 Phosphoinositide 3-kinase (pi3k) inhibitors |
| 01/09/2014 | WO2013175508A3 Stable pharmaceutical composition of aripiprazole |
| 01/09/2014 | WO2013173506A3 Kinase inhibitors for use in the treatment of muscular degradation |
| 01/09/2014 | WO2013172741A3 Fluoro-substituted (3r, 4r, 5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy) cyclohexene-1-carboxylic acids, esters thereof and a method for the use thereof |
| 01/09/2014 | WO2013171204A3 Ophthalmological vehicle system |
| 01/09/2014 | WO2013169977A3 Controlled release solid dose form |
| 01/09/2014 | WO2013169631A3 Wnt protein signalling inhibitors |
| 01/09/2014 | WO2013166438A4 Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use |
| 01/09/2014 | WO2013164839A8 Amorphous form of apixaban, process of preparation and compositions thereof |
| 01/09/2014 | WO2013163562A3 Compositions and methods for treating ptsd and related diseases |
| 01/09/2014 | WO2013156738A3 Lichesterinic acid and the derivatives of same as pigmentation inhibitors |
| 01/09/2014 | WO2013153492A3 Process for the preparation of vilazodone hydrochloride and its amorphous form |
| 01/09/2014 | WO2013141759A3 Use of l-carnosine for the preparation of a nanopreparation having an antihypoxic and antioxidant activity |
| 01/09/2014 | WO2013124026A8 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| 01/09/2014 | WO2013017582A9 Acetone solvate of ivabradine hydrochloride |
| 01/09/2014 | WO2013013815A8 Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
| 01/09/2014 | WO2012162254A8 Inhibitors of lrrk2 kinase activity |
| 01/09/2014 | WO2012135944A9 Protein kinase inhibitors |
| 01/09/2014 | US20140012230 Method and apparatus for treatment of cardiac disorders |
| 01/09/2014 | US20140012042 Calcium Dicarboxylate Ethers |
| 01/09/2014 | US20140012006 Benzimidazole compound crystal |
| 01/09/2014 | US20140011890 Methods and compositions for treating neuropathies |
| 01/09/2014 | US20140011889 Resveratrol-Containing Compositions and Methods of Use for Cardiac-Related Diseases |
| 01/09/2014 | US20140011888 Composition derived from astaxanthin and method to treat joint pain associated with osteoarthritis |
| 01/09/2014 | US20140011887 Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| 01/09/2014 | US20140011885 Organic Compounds |
| 01/09/2014 | US20140011884 Use of s1p receptor modulator |
| 01/09/2014 | US20140011878 High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders |
| 01/09/2014 | US20140011876 Composition and method for treatment of diabetes |
| 01/09/2014 | US20140011874 Treatment of viral infections |
| 01/09/2014 | US20140011873 Compositions and methods of use of phorbol esters for the treatment of stroke |
| 01/09/2014 | US20140011872 Ferric organic compounds, uses thereof and methods of making same |
| 01/09/2014 | US20140011871 Antifungal serum |
| 01/09/2014 | US20140011870 Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
| 01/09/2014 | US20140011869 Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions |
| 01/09/2014 | US20140011868 Use of Simalikalactone E as an Anticancer Agent |
| 01/09/2014 | US20140011864 Transition metal complexes of a bis[thiohydrazide amide] compound |
| 01/09/2014 | US20140011858 Inhibitor of IRS-1 for Treating Skin Disorders |
| 01/09/2014 | US20140011856 Salt form of tyrosine kinase inhibitor |
| 01/09/2014 | US20140011854 ST-246 Liquid Formulations and Methods |
| 01/09/2014 | US20140011853 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy |
| 01/09/2014 | US20140011850 Methods Of Improving Cognitive Function |
| 01/09/2014 | US20140011849 Tricyclic compound and pharmaceutical use thereof |
| 01/09/2014 | US20140011848 Insulin sensitisers and methods of treatment |
| 01/09/2014 | US20140011844 Migrastatin analogs and uses thereof |
| 01/09/2014 | US20140011843 Methods for stabilizing oxidatively unstable compositions |
| 01/09/2014 | US20140011842 Oral Pharmaceutical Dosage Forms |
| 01/09/2014 | US20140011841 Treatment of energy utilization disease |
| 01/09/2014 | US20140011839 Compositions and methods for treating and inhibiting viral infections |